Sharekhan is bullish on Divi’s Laboratories has recommended buy rating on the stock with a target price of Rs 1850 in its research report dated May 28, 2019.
Sharekhan's research report on Divi’s Laboratories
Sales set for healthy growth in the next two years; aggressive capex plan to monetise opportunities in the US and China. Benefits of capex plan to accrue from FY2021; No pending regulatory hurdles. We expect company to report sales and profit CAGRs of 21% and 22%, respectively during FY2019-FY2021E; Q4 earnings lagged estimates due to one-offs.
We maintain our Buy recommendation with a PT of Rs. 1,850.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Subscribe to Moneycontrol Pro and gain access to curated markets data, exclusive trading recommendations, independent equity analysis, actionable investment ideas, nuanced takes on macro, corporate and policy actions, practical insights from market gurus and much more.